Watchlist Price Alert

Immunovant Inc. (IMVT)

NASDAQ: IMVT · Real-Time Price · USD

14.04

-0.26 (-1.82%)

At close: May 09, 2025, 3:59 PM

14.21

1.17%

After-hours: May 09, 2025, 04:48 PM EDT

-1.82% (1D)

Bid	13.98
Market Cap	2.39B
Revenue (ttm)	1.5M
Net Income (ttm)	-382.71M
EPS (ttm)	-2.62
PE Ratio (ttm)	-5.36
Forward PE	-4.54
Analyst	Buy

Ask	14.75
Volume	707,903
Avg. Volume (20D)	1,776,718
Open	14.30
Previous Close	14.30
Day's Range	14.02 - 14.71
52-Week Range	12.72 - 34.47
Beta	0.75

About IMVT

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol IMVT

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for IMVT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

1 month ago

+4.29%

Immunovant shares are trading higher. B of A Secur... Unlock content with Pro Subscription

3 months ago

-9.55%

Immunovant shares are trading lower. The company reported Q3 financial results.

News

1 month ago · zacks.com

IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success

Immunovant's batoclimab shows strong efficacy in MG & CIDP, but shifts focus to the lead drug IMVT-1402 for these indications to induce deeper, lasting relief.

1 month ago · seekingalpha.com

Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward

Immunovant, Inc. reported that positive results were achieved using batoclimab in a phase 3 study to target patients with Myasthenia Gravis; Primary endpoint met. Positive results achieved using batoc...

1 month ago · investors.com

Roivant, Immunovant Succeed In Phase 3. But There's A Twist — And Shares Tumbled.

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval. The post Roivant, Immunovant Succeed In Phase 3.

1 month ago · reuters.com

Immunovant's muscle disorder treatment meets main goal in late-stage trial

Immunovant said on Wednesday its drug for a type of a chronic autoimmune disease that causes muscle weakness met the main goal in a late-stage trial.

2 months ago · zacks.com

Immunovant (IMVT) Loses -15.47% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Immunovant (IMVT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revisin...